TrialJournal of Crohn's & colitis2022

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.

Séverine Vermeire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.